

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司) (於中華人民共和國註冊成立之股份有限公司,在香港以國控股份有限公司之名稱經營業務)

(Stock Code 股份代號:01099)

NOTIFICATION LETTER 通知信函

26 September 2022

Dear Shareholder (Note 1),

SINOPHARM GROUP CO. LTD.* (the "Company") - NOTICE OF PUBLICATION OF 2022 INTERIM REPORT (the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at sinopharm.todayir.com and the HKEXnews's website at www.hkexnews.hk. You may access the Current Corporate Communication under "Investor Relations" on the home page of the Company's website, or browsing through the HKEXnews's website.

You may at any time choose to receive free of charge the Company's Corporate Communications (Note 2) either in printed form in both Chinese and English versions or in Chinese version only or in English version only, or read the website version, notwithstanding any wish to the contrary you have previously conveyed to the Company. If you wish to receive printed version of the Current Corporate Communication, please complete the Request Form on the reverse side and send it to the Company c/o Computershare Hong Kong Investor Services Limited (the "H Share Registrar"), using the pre-paid mailing label at the bottom of the Request Form (if you post in Hong Kong). Otherwise, please affix an appropriate stamp. The address of the H Share Registrar is 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong. The Request Form may also be downloaded from the Company's website at sinopharm.todayir.com or the HKEXnews's website at sww.hkexnews.hk.

If you would like to change your choice of language or means of receipt of the Company's Corporate Communications in the future, please write or send an email to the Company c/o the H Share Registrar at sinopharm.ecom@computershare.com.hk. Even if you have chosen (or are deemed to have consented) to receive the website version of all future Corporate Communications but for any reason you have difficulty in receiving or gaining access to the website version of the Current Corporate Communication, the Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

Should you have any queries relating to any of the above matters, please call the Company's enquiry hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Sinopharm Group Co. Ltd.*
Yu Qingming
Chairman

- * The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."
- Note 1: This letter is being sent to the registered holders of the H shares of the Company, whose names appear on the H share register of members of the Company. If you have sold or transferred all your H shares in the Company, please disregard this letter and the Request Form on its reverse side.
- Note 2: Corporate Communication (the "Corporate Communication") of the Company refers to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the annual report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位股東(附註1):

國藥控股股份有限公司(「本公司」)

- 2022 年中期報告(「本次公司通訊」)之發佈通知

本公司的本次公司通訊中、英文版本已上載於本公司網站 <u>sinopharm.todayir.com</u> 及香港交易所披露易網站 <u>www.hkexnews.hk</u>,歡迎瀏覽。請在本公司網站主頁的「投資者關係」項下,或在香港交易所披露易網站瀏覽有關文件。

儘管 閣下早前曾向本公司作出公司通訊《^{開正》}語言版本或收取方式的選擇,但仍可以隨時更改有關選擇,轉為收取中、英文印刷本、僅收取中文印刷本、僅收取英文印刷本或以網上方式收取,費用全免。如 閣下欲收取本次公司通訊之印刷本,請填妥在本信函背面的申請表格,並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄);否則,請貼上適當的郵票。申請表格請經香港中央證券登記有限公司(「H股登記處」)寄回本公司,H股登記處的地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。申請表格亦可於本公司網站 sinopharm.todayir.com 或香港交易所披露易網站 www.hkexnews.hk 內下載。

如欲選擇有別於 閣下所選擇的本公司公司通訊之語言版本或收取方式,請以書面或以電郵方式 sinopharm.ecom@computershare.com.hk 經 H 股登記處送交到本公司,以更改日後收取公司通訊之語言版本或收取方式之選擇。即使 閣下已選擇(或被視為已同意選擇)收取日後公司通訊之網上版本,但因任何理由以致在收取或閱覽本次公司通訊之網上版本時出現困難,本公司將在 閣下提出要求後立即免費向 閣下寄上本次公司通訊的印刷版本。

如 閣下對本信函內容有任何疑問,請致電本公司電話查詢熱線(852) 2862 8688,辦公時間為星期一至五(公眾假期除外)上午9時正至下午6時正。

代表國藥控股股份有限公司。

于清明

謹 啟

2022 年 9 月 26 日

* 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。

附註 1:本信函收件對象為本公司登記 H 股股東。該等人士的姓名載列於 H 股股東名冊上。如果 閣下已出售或轉讓全部所持有的本公司 H 股股份,則無需要理會本信函及其背面的申 請表格。

附註 2:本公司公司通訊(「公司通訊」)指本公司發出或將予發出以供其任何證券的持有人参照或採取行動的任何文件,其中包括但不限於:(a)年度報告及財務擴要報告(如適用);(b) 中期報告及中期摘要報告(如適用);(c)會議通告;(d)上市文件;(e)通函;及 (f)委任代表表格。

Request Form 申請表格

To: Sinopharm Group Co. Ltd.* (the "Company") (Stock Code: 01099)

> c/o Computershare Hong Kong Investor Services Limited (the "H Share Registrar") 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong

致: 國藥控股股份有限公司(「本公司」)

(股份代號:01099)

經香港中央證券登記有限公司 (「H 股登記處」)

香港灣仔皇后大道東 183 號

合和中心 17M 樓

I/We would like to receive the **CURRENT** Corporate Communication of the Company in the manner as indicated below: 本人/我們現在希望以下列方式收取本公司本次公司通訊:

(Please mark **ONLY ONE** (**X**) of the following boxes) (請從下列選擇中,僅在其中**一個空格**內劃上「X」號)

to receive the printed copy of the Current Corporate Communication in both English and Chinese versions; OR 收取本次公司通訊之中、英文印刷本; 或
to receive the printed copy of the Current Corporate Communication in English version only; OR 僅收取本次公司通訊之英文印刷本; 或
to receive the printed copy of the Current Corporate Communication in Chinese version only. 僅收取本次公司通訊之中文印刷本。

Name(s) of Registered H Share Shareholder(s)# 登記 H 股股東姓名#

Signature

簽名

Address# 地址#

(Please use ENGLISH BLOCK LETTERS 調用英文正楷填寫)

(Please use ENGLISH BLOCK LETTERS 糖用英文正檔道寫)

Contact telephone number 聯絡電話號碼

Date

日期

You are required to fill in the details if you download this Request Form from the Company's Website. 假如你從本公司網站下載本申請表格,請必須填上有關資料。

- Please complete all your details clearly.
- 請 閣下清楚填妥所有資料。 If your H shares are held in joint names, the registered H share shareholder whose name stands first on the H share register of members of the Company in respect of the joint holding
- If your H shares are held in joint names, the registered H share shareholder whose name stands first on the In share register of memorers of the company in respect of the joint names, the register of the company is the part of the labore instruction will apply to the Current joint names, the register of the joint names, the register of the joint names, the register of the joint names, the part of the labore instruction will apply to the Current joint names, the register of the joint names, the part of the labore names in the labore names in
- For the avoidance of doubt, we do not accept any special instructions written on this Request Form. 為免存疑,任何寫在本申請表格上的額外指示,本公司將不予接受。
- Shareholders are entitled to change the choice of language or means of receipt of the Company's Corporate Communications at any time by reasonable notice in writing or by email to the Company c/o the H Share Registrar at sinopharm.ecom@computershare.com.hk.

 股東有權隨時發出合理時間的書面通知或電郵到 sinopharm.ecom@computershare.com.hk 通過 H 股登記處予本公司,要求更改本公司公司通訊之語言版本或收取方式。

The Current Corporate Communication of the Company refers to 2022 Interim Report. 本申請表格所提及之本公司本实公司通訊指 2022 年中期報告。

*The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd." 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回本申請表格時‧請將郵寄標籤剪貼於信封上 如在本港投寄 · 閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry Rate our service

Contact Us 聯繫我們



www.computershare.com/hk/contact